New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens

On April 13, 2022 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported positive preclinical data demonstrating potent T cell responses, potential novel combination use beyond PD-1 inhibitors, and the ability to break immune tolerance to various self-antigens for targeting cancers (Press release, Hookipa Pharma, APR 13, 2022, View Source [SID1234612137]). The results highlight the potential of HOOKIPA’s novel arenaviral platform in difficult-to-treat cancers and as a backbone of potential combination therapies requiring robust T cell responses for cancer patients. The data were shared as poster presentations at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR) (Free AACR Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our HB-200 clinical program biomarker data have confirmed our preclinical findings in head and neck cancers, so we’re encouraged by the preclinical findings presented at AACR (Free AACR Whitepaper) as further evidence of the potential of our novel arenaviral platform in various cancers, either alone or together with other modalities, including as a potential backbone for combination therapy," said Joern Aldag, Chief Executive Officer at HOOKIPA. "Specifically, the ability of our technology to target tumor self-antigens and induce a potent T cell response that leads to tumor regression is important as we prepare to file an IND for our HB-300 program in prostate cancer in the third quarter. In addition, the combination data with 4-1BB or adoptive T cell transfer highlight several new strategies for our platform to amplify T cell responses and address unmet needs in cancer."

All of the AACR (Free AACR Whitepaper) abstract poster presentations are accessible in the Investor section of the HOOKIPA website under "Events."

Potential of arenaviral immunotherapy in combination with other modalities
Preclinical data presented at AACR (Free AACR Whitepaper) (abstract #4198) show that the combination of co-stimulatory 4-1BB agonists with arenaviral immunotherapy increased tumor control and resulted in a higher cure rate than arenaviral immunotherapy alone. Co-stimulatory agents, like 4-1BB agonists, are known as accelerators of cancer immunotherapy, because they help induce potent, tumor-specific T-cells that can infiltrate and kill tumors. The combination of an arenaviral immunotherapy with a 4-1BB agonistic antibody resulted in complete tumor rejection in 30 percent of mice following treatment. Importantly, improved tumor control and cure rates of up to 50 percent were also observed with a 4-1BB ligand which was integrated into the arenaviral vector.

A separate preclinical analysis presented at AACR (Free AACR Whitepaper) (abstract #3298) offered additional evidence of potential combination with other modalities. In this analysis, replicating arenaviral immunotherapy was sequentially combined with adoptively transferred TCR transgenic T cells, which resulted in tumor cures in all mice receiving combination therapy, with 100 percent survival at the end of the experiment (60 days after administration).

These data highlight the potential of arenaviral immunotherapies in combination with other treatment modalities beyond PD-1 inhibitors, as well as showcase the versatility of the platform as a potential backbone for various combination immunotherapies.

Arenaviral immunotherapy activates against self-antigens
Additional preclinical data (abstract #3298 and abstract #4198) showed antitumor activity with a single administration of replicating arenaviral immunotherapy targeting tumor self-antigens. Specifically, the arenaviral immunotherapy was able to overcome immune tolerance, induce potent T cell responses against two different tumor self-antigens and reduce tumor growth in these cancers. Notably, targeting tumor self-antigens can be a challenge because the immune system does not recognize these molecules as foreign.

These preclinical data provide further support for the clinical entry of HOOKIPA’s HB-300 candidate for treatment of prostate cancer. The AACR (Free AACR Whitepaper) data demonstrate the ability of HOOKIPA’s arenaviral immunotherapeutic technology to induce potent T-cell responses against tissue-specific self-antigens, which is the same type of tumor self-antigens targeted by HB-300. The company intends to submit an Investigational New Drug (IND) application in the third quarter of 2022.

HOOKIPA’s Phase 1/2 study (NCT04180215) of HB-200 for patients with Human Papillomavirus 16-positive (HPV16+) squamous cell head and neck cancers (HNSCC) is ongoing. Biomarker data from this study (abstract #3284) showed an unprecedented induction of tumor antigen specific CD8+ T cell responses of up to 40 percent of total CD8+ T cells. As dosing of HB-200 continued, more T cells became polyfunctional (able to produce multiple cytokines), which indicates the T cells are high quality and not exhausted. A clinical update on Phase 1 HB-200 monotherapy data is anticipated mid-year; preliminary data on HB-200 in combination with pembrolizumab as 1st-line and 2nd-line treatment for HNSCC is anticipated in the second half of 2022.

Herantis Pharma Plc – allocation of option rights

On April 13, 2022 Herantis Pharma Plc, Company release, 13 April 2022 at 5:35 p.m. EEST reported that the Board of Directors of Herantis Pharma Plc ("Herantis") has on 13 April 2022 decided to grant a maximum of 168,041 option rights entitling to shares to certain members of the management team under the option rights program 2021 I (Press release, Herantis Pharma, APR 13, 2022, View Source;allocation-of-option-rights,c3546223 [SID1234612136]). The option rights program is based on the authorization granted by the Annual General Meeting held on 15 April 2021 to issue a maximum of 975,000 option rights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Board of Directors has in April 2021 resolved on issuance of a total of 961,221 option rights under the option rights program 2021 I. However, 369,262 of the issued option rights have subsequently been returned to the company as a result of the termination of employment or service relationship of certain persons. The Board of Directors have therefore decided on issuance of these new option rights under the option rights program 2021 I and within the limits of the authorization granted by the Annual General Meeting held on 15 April 2021. The total number of option rights granted and outstanding under the option rights program 2021 I after this issuance is 775,000.

The option rights will be offered without consideration. Each option right entitles to subscribe for one ordinary share in Herantis for a subscription price of EUR 2.60 per share. The subscription price corresponds to 126% of the volume weighted average share price during 10 trading days preceding the grant date of 13 April 2022 (30 March 2022–12 April 2022). The subscription price is higher than the subscription price of the company’s share in the company’s latest share issue against consideration preceding the option grant date.

Granted share options shall vest and become exercisable over a three-year period, with 1/3 becoming exercisable from 13 April 2023, with an annual vesting of 1/3 during the second year after the grant date, and with an annual vesting of 1/3 during the third year after the grant date. The options expire on 13 April 2027 or earlier subject to customary conditions.

OncoNano Medicine Announces Positive Preclinical Data for ONM-501 at AACR 2022 Annual Meeting

On April 13, 2022 OncoNano Medicine, Inc. reported positive results from a preclinical study of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications (Press release, OncoNano Medicine, APR 13, 2022, View Source [SID1234612135]). The data, presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, demonstrate the efficacy and tolerability of ONM-501 in animal models for multiple tumor types. ONM-501 is formulated with the core OncoNano OMNITM polymer technology consisting of STING-activating pH-sensitive micelles loaded with an endogenous agonist.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled by the continued positive preclinical results for ONM-501. STING has consistently been a challenging pathway to target, so we are encouraged by the constellation of our impressive preclinical data showing anti-tumor efficacy and an adaptive response differentiated from cyclic dinucleotide (CDN) STING agonists," said Ruolan Han, Ph.D., Vice President of Nonclinical & Translational Medicine for OncoNano Medicine. "In preclinical studies to date, ONM-501 has demonstrated the ability to produce a burst and sustained activation of the STING signaling pathway that leads to a robust adaptive immune response with low systemic drug exposure and toxicity. We look forward to continuing our IND-enabling activities as we advance ONM-501 toward our first in human trial in early 2023."

ONM-501 was evaluated for anti-tumor efficacy and tolerability in multiple animal oncology models. The findings from multiple preclinical studies evidence the following about ONM-501:

STING activation was observed by measuring IFNB1 and CXCL10 mRNA in PBMCs from different species
Anti-tumor efficacy both as a monotherapy and in combination with anti-PD1 in both immune "hot" and "cold" tumor models
Anti-tumor effect mediated by host STING and dependent on CD8+ T cells
Ability to induce an abscopal effect – tumor inhibition was observed in both primary and distal tumors in the same animal
Ability to induce adaptive immune memory
Ability to inhibit lung metastasis in an immune "cold" triple negative orthotopic breast cancer 4T1 model
Unique nanoparticle formulation delivered intratumorally achieves high local drug retention, low systemic exposure and a potential for a reduced risk of toxicity
Presentation Overview

TITLE: ONM-501: A polyvalent STING agonist for oncology immunotherapy
PRESENTER: Qingtai Su, Ph.D., Senior Scientist, OncoNano Medicine

Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022

On April 13, 2022 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, reported the presentation of preclinical data on the company’s anti-CD27 agonist lead antibodies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022 (Press release, Kineta, APR 13, 2022, View Source;utm_medium=rss&utm_campaign=kineta-unveils-new-preclinical-data-on-its-anti-cd27-agonist-lead-antibodies-at-aacr-2022 [SID1234612134]). Thierry Guillaudeux, PhD, EVP Research and Development at Kineta, presented the company’s poster unveiling new preclinical data. Kineta is developing fully human anti-CD27 agonist antibodies for the treatment of blood cancers and solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Kineta’s anti-CD27 program was developed through our innate immunity expertise and the company’s proprietary PiiONEER platform. We have confirmed very exciting data with our lead anti-CD27 antibodies demonstrating their activity in inducing T cells as well as NK cell activation" said Dr. Guillaudeux. "We are encouraged with these preclinical data and believe that CD27 is an important immuno-oncology target for treating cancer patients with its capability of influencing both the innate and adaptive antitumor immune response ."

Key results from the AACR (Free AACR Whitepaper) poster presentation:

Evaluated 3 lead therapeutic antibodies from our library of 147 fully human anti-CD27 monoclonal antibodies generated in Trianni mice.
Confirmed lead antibodies’ binding potency and cross-reactivity with non-human primate CD27 but not with the murine CD27.
Lead candidates demonstrate strong agonist proprieties. They induce NK cell activation as well as T cell proliferation and activation after engagement of NFκ
Lead antibodies will be evaluated as a single agent or in combination with other immuno-therapies in vivo in solid and hematological mouse tumor models in hCD27-KI mice.
Click on the link below to access the poster

CD27 Publications – Poster Presentation at ESMO (Free ESMO Whitepaper) 2022

Presentation Details

Title: CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Abstract Number: 5588
Presenter: Thierry Guillaudeux, PhD
Session Type: In-Person and e-Poster Presentation
Session Title: Therapeutic Antibodies 3
Session Time: April 13, 2022 9:00AM – 12:30PM Central Time
Location: Poster Section 39

Anti-CD27 mAb program: Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses. Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q2 2022.

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

On April 13, 2022 Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, reported that data being presented in collaboration with Stimunity during the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting taking place April 8-13 in New Orleans, Louisiana (Press release, Portage Biotech, APR 13, 2022, View Source [SID1234612133]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preclinical data shows that PORT-5 (STI-001), a stimulator of interferon genes (STING) agonist, cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) packaged in a virus-like particle (VLP) developed with Stimunity, can be delivered systemically and achieve potent activation of the STING pathway preferentially in dendritic cells. The data will be presented in a late-breaking research session at the AACR (Free AACR Whitepaper) meeting on Wednesday, April 13.

"The promising results showcased in this presentation suggest that we are on the verge of developing a novel approach that could elevate the potential of STING-based therapies," said Dr. Ian Walters, chief executive officer of Portage Biotech. "The data shows that one or more targeted immunotherapy agents could be packaged within a virus-like particle to increase potency, while enabling a selective immune activation. We are glad to see these data showcased at an AACR (Free AACR Whitepaper) late-breaking session and look forward to working with our colleagues at Stimunity to further develop STING agonist treatments."

The STING pathway is a well-recognized immune-boosting pathway that primes an anti-tumor T cell response and has long been an area of interest in cancer treatment, but limitations of small molecule therapies have stymied STING-activating therapies in clinical trials, due to lack of ability to target specific dendritic cells which leads to varied effects in different cells and an inefficient T cell response. Novel approaches are needed to overcome unwanted side effects associated with activation of this pathway in humans. The promising results from Portage and Stimunity show that PORT-5 (STI-001) can not only target specific dendritic cells but can be customized and targeted to specific cell and tumor types across the body and could offer a differentiating option compared to current treatments.

"This presentation is a recognition of the last two years of intense work on the preclinical package of our drug candidate STI-001 in collaboration with Nicolas Manel’s laboratory at Institut Curie / Inserm that demonstrates that packaging a therapeutic modality in a virus-like particle has the potential to unlock systemic delivery for STING via preferential dendritic cell targeting, which is unique in the field," said Sylvain Carlioz, CEO of Stimunity.

Presentation Details:

Abstract title: Cellular selectivity of STING stimulation determines priming of anti-tumor T cell responses
Abstract Number: 7829
Presenter: Bakhos Jneid, Institut Curie
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Date/Time: April 13, 2022, 9:00 a.m. – 12:30 p.m. CT
Location: Poster Section 16
Data Highlights:

Delivery of a well-characterized STING activator, cGAMP, by intra-tumoral injections of virus-like particles (cGAMP-VLP) leads to:
Differentiation of tumor-specific T cells
Decrease in tumor regulatory T cells (Tregs) that would otherwise suppress an immune response
Preferential targeting of dendritic cells leading to activation of tumor-specific T cells
Delivery of PORT-5 (STI-001) showed synergy when combined with an antibody that depletes Tregs, leading to complete and lasting tumor eradication
Additional synergy demonstrated when PORT-5 (STI-001) was combined with anti-PD1 treatments
Specific cell targeting of STING stimulation shapes the anti-tumor T cell response and reveals a therapeutic strategy with T cell modulators, which may address the current limitations of STING-based approaches in patients